By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Novan Therapeutics 

4222 Emperor Boulevard
Suite 470
Durham  North Carolina  27703  U.S.A.
Phone: 919-485-8080 Fax: n/a


SEARCH JOBS


Industry
Biotechnology






Company News
Novan Therapeutics Secures $50 Million Private Financing; Funds Intended to Advance SB204 into Phase 3 3/30/2015 10:43:50 AM
Led By Ex-Elan (ELN) Execs, Malin Rakes in $350 Million and Looks to Invest in Viamet, Novan Therapeutics 3/25/2015 6:27:34 AM
Novan Therapeutics Achieves Target Enrollment For Phase 2 Acne Study 3/18/2015 10:17:59 AM
Novan Therapeutics Expands Leadership Team With Vice President Of Regulatory Affairs 2/26/2015 11:51:11 AM
Novan Therapeutics To Present Successful Clinical Study Results Of Lead Product Candidate SB204 For The Treatment Of Acne Vulgaris 1/15/2015 8:31:52 AM
Novan Therapeutics’s Nitric Oxide Drug Candidate Inhibits Growth Of Papillomavirus In Translational Animal Model 9/8/2014 10:40:06 AM
Novan Therapeutics’s Nitricil™ Technology Shows Efficacy Against Multidrug Resistant Superbugs 8/19/2014 10:10:36 AM
Novan Therapeutics To Present Antiviral Preclinical Results Of Nitric Oxide-Releasing Drug Candidates For The Treatment Of Papillomavirus 8/14/2014 8:01:21 AM
Novan Therapeutics’ Pipeline Fueled By Public-Private Partnerships Receives National Recognition 6/19/2014 10:00:38 AM
Novan Therapeutics' Positive Phase 2 Results Provide Foundation For SB204 As A Non-Antibiotic, First-In-Class Product To Treat Acne Vulgaris 5/8/2014 7:16:05 AM
12
//-->